Eli Lilly & Co. Chief Executive Officer David Ricks bought 1,632 company shares for about $1.05 million, paying an average $644.77 apiece, according to a filing with the U.S. Securities and Exchange Commission. Chief Scientific Officer Daniel Skovronsky added 1,000 shares for roughly $634,000 at $634.41 each, and several other senior managers also reported six- to seven-figure open-market purchases. The insider buying follows a roughly 13% slide in Lilly’s stock last week after early data on its experimental oral GLP-1 weight-loss pill, orforglipron, fell short of some investors’ expectations. On Tuesday the company said it had completed a Phase 3 trial of orforglipron in Japanese adults, describing the results as promising as it races Novo Nordisk and other rivals in the fast-growing obesity-drug market. Asset-manager BlackRock holds just under 7% of Lilly’s outstanding shares. While Lilly executives signal confidence by adding to their holdings, Hims & Hers Health is seeing the opposite move. Chief Executive Officer Andrew Dudum sold about $33.4 million of his company’s stock at an average $50.58 a share, marking the largest insider sale since the telehealth provider went public four years ago. The transaction came after a steep rally in Hims & Hers shares this year.